Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08049820 dose-ranging study in adults with moderate to severe atopic dermatitis
jRCT2031250615Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing PF-08049820 with Placebo (2 arms). Primary endpoint: Percent change from baseline in Eczema Area and Severity Index total score at Week 12. Started Jun 2026; status: recruiting.
02
Drugs
PF-08049820
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031250615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250615.